Sanofi beat out 3 suitors and one last-minute bid in its pricey $2.5B Synthorx buyout

When Sanofi picked up biotech Synthorx for a cool $2.5 billion in December, it paid a rich premium to enter an increasingly competitive space for IL-2 immunotherapies. But in the face of stiff competition, sometimes a blow-away bid is what it takes to win the day.